7.58
price up icon0.80%   0.06
after-market Handel nachbörslich: 7.58
loading
Schlusskurs vom Vortag:
$7.52
Offen:
$7.56
24-Stunden-Volumen:
1.65M
Relative Volume:
0.69
Marktkapitalisierung:
$553.27M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-1.6231
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+2.43%
1M Leistung:
+1.88%
6M Leistung:
-58.40%
1J Leistung:
-73.86%
1-Tages-Spanne:
Value
$7.47
$7.73
1-Wochen-Bereich:
Value
$7.32
$7.93
52-Wochen-Spanne:
Value
$5.90
$30.31

Arvinas Inc Stock (ARVN) Company Profile

Name
Firmenname
Arvinas Inc
Name
Telefon
203-535-1456
Name
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Name
Mitarbeiter
430
Name
Twitter
@ArvinasInc
Name
Nächster Verdiensttermin
2025-02-11
Name
Neueste SEC-Einreichungen
Name
ARVN's Discussions on Twitter

Vergleichen Sie ARVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARVN
Arvinas Inc
7.58 540.14M 161.10M -308.60M -259.90M -4.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Arvinas Inc Stock (ARVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-02 Herabstufung Leerink Partners Outperform → Market Perform
2025-05-05 Herabstufung Truist Buy → Hold
2025-05-02 Herabstufung Jefferies Buy → Hold
2025-05-02 Herabstufung TD Cowen Buy → Hold
2025-03-13 Herabstufung Goldman Buy → Neutral
2025-03-12 Herabstufung Wedbush Outperform → Neutral
2025-03-11 Herabstufung Oppenheimer Outperform → Perform
2024-12-10 Eingeleitet BTIG Research Buy
2024-11-18 Eingeleitet Stephens Overweight
2024-02-28 Bestätigt Oppenheimer Outperform
2024-02-14 Herabstufung Citigroup Buy → Neutral
2024-02-01 Eingeleitet Goldman Buy
2023-12-19 Hochstufung Wells Fargo Equal Weight → Overweight
2023-12-06 Hochstufung Jefferies Hold → Buy
2023-11-20 Hochstufung Guggenheim Neutral → Buy
2023-10-23 Hochstufung Wedbush Neutral → Outperform
2023-06-26 Fortgesetzt Oppenheimer Outperform
2023-01-12 Herabstufung Guggenheim Buy → Neutral
2023-01-03 Herabstufung Wells Fargo Overweight → Equal Weight
2022-09-09 Eingeleitet Barclays Overweight
2022-06-21 Eingeleitet Jefferies Hold
2022-05-09 Herabstufung Wedbush Outperform → Neutral
2022-04-28 Eingeleitet Credit Suisse Outperform
2022-04-06 Eingeleitet Morgan Stanley Equal-Weight
2022-02-11 Fortgesetzt BMO Capital Markets Outperform
2022-02-10 Eingeleitet Wells Fargo Overweight
2022-01-19 Eingeleitet Goldman Buy
2021-12-07 Eingeleitet Cowen Outperform
2021-10-14 Eingeleitet SVB Leerink Outperform
2021-09-30 Eingeleitet Stifel Buy
2021-09-09 Eingeleitet BofA Securities Buy
2021-05-21 Eingeleitet UBS Buy
2021-04-21 Eingeleitet Truist Buy
2021-03-31 Eingeleitet BMO Capital Markets Outperform
2020-12-14 Hochstufung Oppenheimer Perform → Outperform
2020-06-01 Hochstufung Citigroup Neutral → Buy
2020-05-12 Eingeleitet Oppenheimer Perform
2019-12-19 Eingeleitet H.C. Wainwright Buy
2019-11-25 Eingeleitet Guggenheim Buy
2019-10-24 Hochstufung Goldman Neutral → Buy
2019-09-25 Eingeleitet Wedbush Outperform
2019-09-12 Eingeleitet BMO Capital Markets Outperform
2019-08-06 Eingeleitet Cantor Fitzgerald Overweight
2019-06-05 Herabstufung Citigroup Buy → Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2018-10-22 Eingeleitet Citigroup Buy
2018-10-22 Eingeleitet Goldman Neutral
2018-10-22 Eingeleitet Piper Jaffray Overweight
Alle ansehen

Arvinas Inc Aktie (ARVN) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Arvinas Inc. stock priceExplosive returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Arvinas Inc. stockFastest-growing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Arvinas (ARVN) to Release Earnings on Tuesday - MarketBeat

Jul 22, 2025
pulisher
Jul 20, 2025

Is Arvinas Inc. a good long term investmentSignificant capital appreciation - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment - MSN

Jul 20, 2025
pulisher
Jul 20, 2025

Arvinas Inc. Stock Analysis and ForecastFree Stock Selection - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 18, 2025

Arvinas, Inc. (NASDAQ:ARVN) Receives $20.29 Consensus Price Target from Analysts - MarketBeat

Jul 18, 2025
pulisher
Jul 15, 2025

13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey

Jul 15, 2025
pulisher
Jul 14, 2025

(ARVN) Proactive Strategies - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 13, 2025

Arvinas (NASDAQ:ARVN) Trading Down 4.6%Here's Why - MarketBeat

Jul 13, 2025
pulisher
Jul 13, 2025

Arvinas: A Potential 'Sum Of The Parts' Story (NASDAQ:ARVN) - Seeking Alpha

Jul 13, 2025
pulisher
Jul 10, 2025

Arvinas CEO John Houston to retire - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Arvinas stock slides after eliminating trials, reducing workforce - MSN

Jul 10, 2025
pulisher
Jul 10, 2025

Arvinas CEO John Houston to retire, remain as board chair By Investing.com - Investing.com South Africa

Jul 10, 2025
pulisher
Jul 09, 2025

Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas (ARVN) Soars 2.62% on CEO Transition - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas CEO John Houston to retire, remain as board chair - Investing.com Australia

Jul 09, 2025
pulisher
Jul 09, 2025

Gilead signs lenacapavir access deal; Arvinas CEO to step down - BioPharma Dive

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas Announces Retirement of CEO John Houston, Ph.D., - citybiz

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas CEO John Houston to retire after successor is named, will remain board chair - Investing.com Nigeria

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas CEO John Houston to retire after successor is named, will remain board chair By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas' CEO to Retire; Search for Successor Begins - MarketScreener

Jul 09, 2025
pulisher
Jul 09, 2025

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan - The Manila Times

Jul 09, 2025
pulisher
Jul 09, 2025

Pioneering Biotech CEO Steps Down: How Arvinas' Houston Transformed Protein Degradation Drug Development - Stock Titan

Jul 09, 2025
pulisher
Jun 30, 2025

Arvinas announces board resignation and reports annual meeting voting results By Investing.com - Investing.com South Africa

Jun 30, 2025
pulisher
Jun 30, 2025

Arvinas, Inc. Announces John Young Decides to Resign from its Board of Directors and Compensation Committee, Effective June 30, 2025 - MarketScreener

Jun 30, 2025
pulisher
Jun 30, 2025

Arvinas announces board resignation and reports annual meeting voting results - Investing.com

Jun 30, 2025
pulisher
Jun 28, 2025

Arvinas, Inc. (NASDAQ:ARVN) CFO Andrew Saik Sells 5,700 Shares - MarketBeat

Jun 28, 2025
pulisher
Jun 23, 2025

Bragar Eagel & Squire, P.C. Is Investigating Arvinas, Semler, and Abacus and Encourages Investors to Contact the Firm - TradingView

Jun 23, 2025
pulisher
Jun 20, 2025

Arvinas (NASDAQ:ARVN) Shares Gap UpStill a Buy? - MarketBeat

Jun 20, 2025
pulisher
Jun 18, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Logos Global Management LP Issues a Letter to the Board of Arvinas, Inc. - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Wall Street Analysts Believe Arvinas (ARVN) Could Rally 89.85%: Here's is How to Trade - MSN

Jun 17, 2025
pulisher
Jun 14, 2025

Arvinas’s SWOT analysis: vepdegestrant efficacy fuels stock potential amid market challenges - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Analysts Set Expectations for Arvinas FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

ARVN: Arvinas' ARV-393 Shows Promise in Preclinical Lymphoma Stu - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Says ARV-393 Preclinical Studies Show 'Significant' Single-Agent Activity in Certain Lymphoma - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV- - GuruFocus

Jun 13, 2025

Finanzdaten der Arvinas Inc-Aktie (ARVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):